ArticleJournal, genetic engineering & biotechnology2025
Computational and molecular insights on non-synonymous SNPs associated with human RAAS genes: Consequences for Hypertension vulnerability.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- HTSNPedia: A Molecular Perspective and Risk Estimator Database for Hypertension-Associated Genes.Biochemical genetics · 2026Article
- Comprehensive In Silico Analysis of the CXCL12, C55Y Mutation Reveals Structural and Functional Disruption in CXCR4/CXCR7 Signaling.Evolutionary bioinformatics online · 2026Article
- Inflammatory Pathways and Immune Microenvironment in Non-Small Cell Lung Cancer: Multi-Dimensional Analysis and Machine Learning Prediction.Journal of cellular and molecular medicine · 2025Article
- Deciphering highly potent natural abscisic acid agonists for binding to pyrabactin resistance 1 receptor through computational approaches.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is the foremost modifiable risk factor for cardiovascular and renal diseases, and overall mortality on a global scale. Genetic variants have the potential to alter an individual's drug responses. In the present study, we employed a comprehensive computational analysis to evaluate the structural and functional implications of deleterious missense variants to examine the influence of RAAS genes such as AT1R, AT2R, and MasR on susceptibility to hypertension. The objective of this research was to identify potentially deleterious missense variants within these target genes. A total of 13 in silico tools were used to identify deleterious missense SNPs. Protein stability, evolutionary conservation, and 3D structural modeling were assessed using tools like I-Mutant 3.0, MUpro, DynaMut2, ConSurf, and Project HOPE, while protein-protein interactions were analyzed via STRING. Our findings revealed three deleterious missense variants (rs397514687, rs886058071, rs368951368) in AT1R; two deleterious missense variants (rs3729979 and rs372930194) in AT2R; and three deleterious missense variants (rs768037685, rs149100513, and rs377679974) in MasR, all of which exhibited significant damaging effects as determined by the 13 Computational tools employed. All these deleterious missense variants adversely affected protein stability and were found to be highly conserved. Notably, these variants altered the charge, size, and hydrophobicity of the amino acids, with a predominant occurrence in alpha helix regions, with the exception of rs377679974 in MasR. The computational analysis and structural comparisons conducted in this study indicate that these deleterious missense variants have a discernible impact on the structure and function of the target proteins. However, it is essential to conduct experimental validation to verify the detrimental effects of the missense variants identified through this computational analysis. Therefore, we may conduct future experimental analyses to validate these findings. This research will aid in the identification of candidate deleterious markers that may serve as potential targets for therapeutic strategies and disease diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.